Development Of Januvia-Lipitor Combo Ends

Tue, 11/13/2012 - 1:47pm

Merck & Co. has disclosed that it is ending development of a pill that combines its diabetes drug Januvia with atorvastatin, the main ingredient in Lipitor.

Merck cited unspecified business reasons for ending clinical work on the pill, which was designated MK-0431E. It disclosed the move in a form filed with the Securities and Exchange Commission.

Januvia is the Whitehouse Station, N.J., company's best-selling drug. In the third quarter revenue from Januvia rose 15% to $975 million. That was 50% more revenue than its next biggest product, the cholesterol drug Zetia.

Lipitor is marketed by Pfizer Inc. It was the best-selling drug in history, but lost patent protection about a year ago, allowing generic versions to reach the market.

Date: November 13, 2012
Source: Associated Press


Share This Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.